EIF3LP3: A Potential Drug Target and Biomarker (G340947)
EIF3LP3: A Potential Drug Target and Biomarker
Eukaryotic translation initiation factor 3 (EIF3) is a protein that plays a crucial role in the initiation of protein translation in eukaryotic cells. The protein encoded by the EIF3 gene is composed of multiple subunits, including the EIF3 subunit L pseudogene 3 (EIF3LP3). EIF3LP3 is a pseudogene, which means that it is a non-coding gene that has been shown to encode a protein.
Recent studies have identified EIF3LP3 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. In this article, we will discuss the recent findings on EIF3LP3 and its potential as a drug target and biomarker.
Potential Drug Target
EIF3LP3 has been identified as a potential drug target due to its involvement in various cellular processes that are associated with the development and progression of various diseases. EIF3 is a key factor in the initiation of protein translation, which is the process by which proteins are synthesized from mRNA. Therefore, alterations in the translation process can lead to changes in cellular behavior and contribute to the development of diseases.
Studies have shown that EIF3LP3 is involved in various cellular processes that are associated with the development of cancer, neurodegenerative diseases, and autoimmune diseases. For example, EIF3LP3 has been shown to be involved in the regulation of cell adhesion, which is a process that is critical for the maintenance of tissue structure and function. Additionally, EIF3LP3 has been shown to be involved in the regulation of the cytoskeleton, which is a structure that is critical for the proper functioning of cells.
Biomarker
EIF3LP3 has also been identified as a potential biomarker for various diseases. The detection and quantification of EIF3LP3 have been shown to be useful for the diagnosis and monitoring of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.
For example, studies have shown that EIF3LP3 levels are significantly increased in various types of cancer, including breast, lung, and ovarian cancer. Additionally, EIF3LP3 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.
Conclusion
In conclusion, EIF3LP3 is a pseudogene that has been shown to encode a protein that plays a crucial role in the initiation of protein translation in eukaryotic cells. The recent studies have identified EIF3LP3 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Further studies are needed to confirm its potential as a drug and to develop new diagnostic tests for EIF3LP3.
Protein Name: Eukaryotic Translation Initiation Factor 3 Subunit L Pseudogene 3
More Common Targets
EIF3M | EIF4A1 | EIF4A1P4 | EIF4A2 | EIF4A2P4 | EIF4A2P5 | EIF4A3 | EIF4B | EIF4BP1 | EIF4BP3 | EIF4BP7 | EIF4BP9 | EIF4E | EIF4E1B | EIF4E2 | EIF4E3 | EIF4EBP1 | EIF4EBP2 | EIF4EBP3 | EIF4ENIF1 | EIF4F translation-initiation complex | EIF4G1 | EIF4G2 | EIF4G3 | EIF4H | EIF4HP2 | EIF5 | EIF5A | EIF5A2 | EIF5AL1 | EIF5B | EIF6 | EIPR1 | ELAC1 | ELAC2 | ELANE | ELAPOR1 | ELAPOR2 | Elastase | ELAVL1 | ELAVL2 | ELAVL3 | ELAVL4 | ELDR | ELF1 | ELF2 | ELF2P4 | ELF3 | ELF3-AS1 | ELF4 | ELF5 | ELFN1 | ELFN1-AS1 | ELFN2 | ELK1 | ELK2AP | ELK3 | ELK4 | ELL | ELL2 | ELL2P1 | ELL3 | ELMO1 | ELMO2 | ELMO3 | ELMOD1 | ELMOD2 | ELMOD3 | ELN | ELOA | ELOA-AS1 | ELOA2 | ELOA3BP | ELOA3DP | ELOA3P | ELOB | ELOC | ELOF1 | Elongation Factor 1 Complex | Elongation of very long chain fatty acids protein | Elongin (SIII) complex | ELOVL1 | ELOVL2 | ELOVL2-AS1 | ELOVL3 | ELOVL4 | ELOVL5 | ELOVL6 | ELOVL7 | ELP1 | ELP2 | ELP3 | ELP4 | ELP5 | ELP6 | ELSPBP1 | EMB | EMBP1 | EMC1 | EMC1-AS1